Oncogene Cancer Research shared on LinkedIn:
“Today, on World Lung Cancer Day, we’re proud to join forces with Young Lung Cancer Initiative and EGFR Resisters on a global campaign highlighting an uncomfortable truth:
Where you’re born can influence whether your lung cancer is detected early, whether you’re offered biomarker testing, and sometimes even the treatment that could give you more time.
Across Japan, the US, Ireland, Chile, Canada, Puerto Rico, South Africa and beyond, every face in this campaign tells a different story.
- In Japan, nationwide screening is available.
- In parts of the US, access to biomarker testing can depend on which side of a state border you live.
- In Canada, screening eligibility varies by province.
- In Puerto Rico, people remain underrepresented in the research that should help guide their care.
The science exists. Too often, equitable access does not.
On this WLCD26, we’re standing together to say that your postcode, province or passport should never determine your opportunity for early diagnosis, precision medicine or the best possible care.
Different countries. Different healthcare systems.
The same disease. The same hope. The same right to more time.
We’d love to hear from colleagues, clinicians, researchers, advocates and patients around the world.
What is one thing about lung cancer care in your country that others might be surprised to learn? Share your country in the comments and help us build a global picture of where progress is happening – and where change is still urgently needed.”
